US Patent 11547718 Modulators of FOXP3 expression
Patent 11547718 was granted and assigned to Ionis Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 24 Nov, 2023
Megan Gustafson
Edits made to:
Infobox (+1/-1 properties)
Infobox
Current Assignee
00
Current Assignee
Megan Gustafson
Edits made to:
Infobox (+1/-1 properties)
Infobox
Patent Applicant
00
Patent Applicant
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
115477180
Date of Patent
January 10, 2023
0Patent Application Number
166842710
Date Filed
November 14, 2019
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 11 Jan, 2023
Golden AI
Edits made to:
Infobox (+12 properties)
Article (+178 characters)
US Patent 11547718 Modulators of FOXP3 expression
Article
The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer.
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
115477180
Date of Patent
January 10, 2023
0Patent Application Number
166842710
Date Filed
November 14, 2019
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11547718 Modulators of FOXP3 expression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.